Simplify Logo

Full-Time

Associate Director

Formulation Development

Confirmed live in the last 24 hours

Pliant Therapeutics

Pliant Therapeutics

51-200 employees

Develops treatments for fibrotic diseases

Hardware
Biotechnology

Compensation Overview

$200k - $210kAnnually

+ Equity + Annual Target Bonus

Senior, Expert

San Bruno, CA, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. / M.S in Pharmaceutical Science or related field.
  • 8+ years’ experience in pre-formulation and formulation development for small molecules, preferably solid dosage forms, 5+ years in managing outsourced development activities.
  • Experience in formulation and process development for late phase development; preferably with direct experience with late-stage oral solid dose manufacturing process.
  • Good working knowledge of GMP requirements for drug product development and manufacturing.
  • Good understanding of ICH, FDA, EMA guidance’s in CMC and Quality areas.
  • Effective written and oral communication and interpersonal skills.
  • Experience in leading formulation projects in pre-formulation, formulation development, and process selection and scale up, and oversight of GMP manufacturing of drug products.
  • Excel in team settings with ability to think critically and work independently.
Responsibilities
  • Design and execute development and characterization studies to evaluate formulations, primary container closure systems, and drug product manufacturing unit operations.
  • Work closely with the Pliant team to develop and evaluate formulation and process development related activities at both in-house Pliant labs and at CMOs.
  • Develop strategies and execute plans for drug product development from first time in human formulations through development of NDA ready formulations in accordance with timelines and requirements of overall development programs.
  • Screen and help identify drug product manufacturing CMOs for Pliant programs.
  • Lead formulation and process development, technology transfer, scale-up, and clinical manufacturing activities at CMO sites.
  • Review and approve manufacturing documents, protocols, and reports.
  • Support manufacturing and quality in problem solving production issues and deviation investigations.
  • Design and execute statistical design of experiments (DoE) studies to evaluate formulations and process prior to transfer and during scaled production at CMOs.
  • Design, develop and execute late-stage process development and optimization activities to identity CPPs, CQAs etc. leading into commercial process validation.
  • Write technical reports and author CMC sections of regulatory submissions related to drug product from IND through NDA stage of development.
  • Be self-motivated and organized and familiar with the relevant literature.

Pliant Therapeutics develops treatments for fibrotic diseases, which cause thickening and scarring of connective tissue, leading to organ dysfunction. Their products work by targeting the biological mechanisms behind fibrosis, particularly through the inhibition of integrins, which are proteins that help cells stick together and communicate. This targeted approach allows Pliant to create effective treatments for various fibrotic conditions. Unlike many competitors, Pliant focuses specifically on the science of fibrosis and integrin biology, aiming to reverse the effects of these diseases rather than just manage symptoms. The company's goal is to halt the progression of fibrotic diseases and restore normal organ function, ultimately improving the quality of life for patients.

Company Stage

IPO

Total Funding

$694.9M

Headquarters

San Francisco, California

Founded

2015

Growth & Insights
Headcount

6 month growth

12%

1 year growth

17%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • Pliant's accelerated development of bexotegrast for IPF and positive Phase 2a trial results indicate strong potential for successful market entry.
  • The company's participation in high-profile investor events and scientific congresses enhances its visibility and credibility in the biotech community.
  • Recent strategic appointments, including a new Chief Development Officer and Chief Regulatory Officer, bolster Pliant's leadership team and operational capabilities.

What critics are saying

  • The high costs and long timelines associated with drug development pose financial risks, especially if clinical trials do not meet endpoints.
  • The competitive landscape in biopharmaceuticals, particularly in fibrosis treatment, requires Pliant to continuously innovate to maintain its edge.

What makes Pliant Therapeutics unique

  • Pliant Therapeutics focuses specifically on fibrotic diseases, leveraging deep expertise in fibrosis and integrin biology, unlike competitors with broader therapeutic areas.
  • Their targeted approach to integrin inhibition offers a unique mechanism of action that sets them apart from other fibrosis treatments.
  • Pliant's commitment to rigorous clinical trials and data-driven development ensures high standards of efficacy and safety, distinguishing them in the biopharmaceutical market.